Global Optimization of Ventricular Myocyte Model to Multi-Variable Objective Improves Predictions of Drug-Induced Torsades de Pointes
Open Access
- 19 December 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 8, 1059
Abstract
In silico cardiac myocyte models present powerful tools for drug safety testing and for predicting phenotypical consequences of ion channel mutations, but their accuracy is sometimes limited. For example, several models describing human ventricular electrophysiology perform poorly when simulating effects of long QT mutations. Model optimization represents one way of obtaining models with stronger predictive power. Using a recent human ventricular myocyte model, we demonstrate that model optimization to clinical long QT data, in conjunction with physiologically-based bounds on intracellular calcium and sodium concentrations, better constrains model parameters. To determine if the model optimized to congenital long QT data better predicts risk of drug-induced long QT arrhythmogenesis, in particular Torsades de Pointes risk, we tested the optimized model against a database of known arrhythmogenic and non-arrhythmogenic ion channel blockers. When doing so, the optimized model provided an improved risk assessment. In particular, we demonstrate an elimination of false-positive outcomes generated by the baseline model, in which simulations of non-torsadogenic drugs, in particular verapamil, predict action potential prolongation. Our results underscore the importance of currents beyond those directly impacted by a drug block in determining torsadogenic risk. Our study also highlights the need for rich data in cardiac myocyte model optimization and substantiates such optimization as a method to generate models with higher accuracy of predictions of drug-induced cardiotoxicity.Keywords
Funding Information
- Foundation for the National Institutes of Health (U01HL136297)
This publication has 43 references indexed in Scilit:
- Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk AssessmentFrontiers in Physiology, 2017
- Quantitative Comparison of Effects of Dofetilide, Sotalol, Quinidine, and Verapamil between Human Ex vivo Trabeculae and In silico Ventricular Models Incorporating Inter-Individual Action Potential VariabilityFrontiers in Physiology, 2017
- Differential roles of two delayed rectifier potassium currents in regulation of ventricular action potential duration and arrhythmia susceptibilityThe Journal of Physiology, 2016
- The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progressJournal of Pharmacological and Toxicological Methods, 2016
- A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay ParadigmSLAS Discovery, 2016
- hERG Inhibitors with Similar Potency But Different Binding Kinetics Do Not Pose the Same Proarrhythmic Risk: Implications for Drug Safety AssessmentJournal of Cardiovascular Electrophysiology, 2013
- An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessmentAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Rapid Genetic Algorithm Optimization of a Mouse Computational Model: Benefits for Anthropomorphization of Neonatal Mouse CardiomyocytesFrontiers in Physiology, 2012
- Support Vector Machines and Kernels for Computational BiologyPLOS Computational Biology, 2008
- Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure.Circulation, 1992